Evidence map›Paper›PMID 42232184›Full record

ReviewFrontiers in pharmacology2026

Natural products in treating sepsis-associated lung and liver injuries by mediating ferroptosis, current progress, and future perspective.

Jingjing Li, Xiaolan Xia, Kun Wang, Xia Xu, Chun Li

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jingjing LiDepartment of Pharmacy, Wuhou District People's Hospital, Chengdu, Sichuan Wuhou District Maternal and Child Health Hospital, Chengdu, Sichuan, China.
Xiaolan XiaDepartment of Pharmacy, Wuhou District People's Hospital, Chengdu, Sichuan Wuhou District Maternal and Child Health Hospital, Chengdu, Sichuan, China.
Kun WangDepartment of Pharmacy, Wuhou District People's Hospital, Chengdu, Sichuan Wuhou District Maternal and Child Health Hospital, Chengdu, Sichuan, China.
Xia XuDepartment of Pharmacy, Wuhou District People's Hospital, Chengdu, Sichuan Wuhou District Maternal and Child Health Hospital, Chengdu, Sichuan, China.
Chun LiDepartment of Pharmacy, Wuhou District People's Hospital, Chengdu, Sichuan Wuhou District Maternal and Child Health Hospital, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a life-threatening disorder triggered by an unregulated host reaction to infection, and it represents a worldwide health dilemma given the scarcity of effective treatment strategies. Sepsis usually leads to lethal multiorgan dysfunctions, including acute liver failure (ALF) and acute lung injury (ALI). Recent studies have found that altered programmed cell death (PCD) processes, including apoptosis, autophagy, ferroptosis, and pyroptosis, belong to key mechanisms that trigger sepsis-associated multiorgan disorders. Among them, ferroptosis is a unique mode of PCD characterized by the accumulation of iron-dependent reactive oxygen species (ROS) and lipid peroxidation. Mediating ferroptosis is a promising strategy against sepsis. Recently, studies have identified multiple natural products for treating sepsis-associated lung and liver injuries by targeting ferroptosis. Here, we provide an overview of the mechanisms and potential therapeutic targets underlying ferroptosis in sepsis. The natural products with ferroptosis targeting will be summarized. Notably, most current evidence supporting the therapeutic potential of natural products is derived from preclinical investigations, and high-quality clinical data remain scarce, requiring further validation for clinical translation. We hope this study provides new perspectives for the future treatment of sepsis-induced ALI and ALF.

Indexed as

acute lung injuryferroptosisliver injurynatural productssepsis

Identifiers

PMID42232184
PMCPMC13223373

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.